# Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis

> **NCT00750139** · PHASE3 · COMPLETED · sponsor: **Merz North America, Inc.** · enrollment: 707 (actual)

## Conditions studied

- Tinea Pedis
- Athlete's Foot

## Interventions

- **DRUG:** NAFT-500
- **DRUG:** Placebo 2-weeks
- **DRUG:** Naftin 1%
- **DRUG:** Placebo 4-weeks

## Key facts

- **NCT ID:** NCT00750139
- **Lead sponsor:** Merz North America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-08
- **Final completion:** 2009-12
- **Target enrollment:** 707 (ACTUAL)
- **Last updated:** 2013-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00750139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00750139, "Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00750139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*